This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Basta, G. Articles by Gastaldelli, A. Search for Related Content PubMed PubMed Citation Articles by Basta, G. Articles by Gastaldelli, A. Related Collections Cardiovascular Endocrinology Diabetes and Insulin

Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein

Consiglio Nazionale delle Richerche Institute of Clinical Physiology (G.B., A.M.S., G.L., S.D.T., E.B., E.F., A.G.) and Department of Internal Medicine (A.C., A.N., E.F.), University of Pisa School of Medicine, 56124 Pisa, Italy

Address all correspondence and requests for reprints to: Giuseppina Basta, DBiol, Consiglio Nazionale delle Richerche Institute of Clinical Physiology, Via Moruzzi, 1, 56124 Pisa, Italy. E-mail: lapina{at}ifc.cnr.it.

Context: The interaction of advanced glycation end products, including N-(carboxymethyl)lysine-protein adducts (CML) and S100A12 protein, with their cellular receptor (RAGE) is implicated in the pathogenesis of diabetic vascular complications. RAGE has a circulating secretory receptor form, soluble RAGE (sRAGE), which, by neutralizing the action of advanced glycation end products, might exert a protective role against the development of cardiovascular disease.

Objective: The objective of the study was to investigate whether plasma sRAGE levels are associated with glycemic control, proinflammatory factors, or circulating ligands of RAGE such as plasma CML and S100A12 protein.

Study Design: We studied 160 subjects, 84 subjects with type 2 diabetes (aged 60 ± 7 yr) and 76 nondiabetic controls (aged 45 ± 10 yr).

Results: Plasma sRAGE was lower in diabetic patients than controls [141 (53–345) vs. 735 (519–1001) pg/ml, median (interquartile range), P < 0.0001], whereas CML levels were higher in diabetic patients than controls [67.9 (46.0–84.7) vs. 43.4 (28.0–65.0) µg/ml, P < 0.0001]. In stepwise regression analysis of the whole data set, hemoglobin A_1c, insulin resistance (as homeostasis model assessment), and C-reactive protein were independently associated with plasma sRAGE, whereas age was not. In a subgroup of 26 diabetic and 24 nondiabetic subjects of similar age (54 ± 3 yr), plasma S100A12 levels were higher in diabetic subjects [49 (39–126) vs. 28 (21–39) ng/ml]. Moreover, low sRAGE and high S100A12 were strongly associated with increased risk for cardiovascular disease (Framingham score). In this subgroup, the plasma S100A12 level was the only determinant of plasma sRAGE concentration.

Conclusion: Plasma level of sRAGE is down-regulated in chronic hyperglycemia; among its ligands, S100A12 protein, but not CML, appears to be associated with this effect.

This article has been cited by other articles:

				H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology, October 1, 2009; 48(10): 1190 - 1196. [Abstract] [Full Text] [PDF]

				V. Tchaikovski, S. Olieslagers, F.-D. Bohmer, and J. Waltenberger Diabetes Mellitus Activates Signal Transduction Pathways Resulting in Vascular Endothelial Growth Factor Resistance of Human Monocytes Circulation, July 14, 2009; 120(2): 150 - 159. [Abstract] [Full Text] [PDF]

				A. Z. Kalea, N. Reiniger, H. Yang, M. Arriero, A. M. Schmidt, and B. I. Hudson Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene FASEB J, June 1, 2009; 23(6): 1766 - 1774. [Abstract] [Full Text] [PDF]

				N. Katakami, M. Matsuhisa, H. Kaneto, T.-A. Matsuoka, K. Sakamoto, T. Yasuda, and Y. Yamasaki Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 190 - 197. [Abstract] [PDF]

				Z Sternberg, B Weinstock-Guttman, D Hojnacki, P Zamboni, R Zivadinov, K Chadha, A Lieberman, L Kazim, A Drake, P Rocco, et al. Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity Multiple Sclerosis, July 1, 2008; 14(6): 759 - 763. [Abstract] [PDF]

				B. I. Hudson, A. M. Carter, E. Harja, A. Z. Kalea, M. Arriero, H. Yang, P. J. Grant, and A. M. Schmidt Identification, classification, and expression of RAGE gene splice variants FASEB J, May 1, 2008; 22(5): 1572 - 1580. [Abstract] [Full Text] [PDF]

				M. Kalousova, M. Jachymova, O. Mestek, M. Hodkova, M. Kazderova, V. Tesar, and T. Zima Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2020 - 2026. [Abstract] [Full Text] [PDF]